127 related articles for article (PubMed ID: 37805968)
1. Clinical utility of a cytomegalovirus-specific T cell assay in assessing the risk of post-prophylaxis cytomegalovirus infection and post-treatment relapse.
Dioverti MV; Bhaimia E; Yetmar ZA; Melendez DP; Misner L; Beito E; Deziel PJ; Theel ES; Razonable RR
Clin Transplant; 2023 Dec; 37(12):e15143. PubMed ID: 37805968
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
[TBL] [Abstract][Full Text] [Related]
3. Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity.
Jorgenson MR; Kleiboeker H; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
Transpl Infect Dis; 2022 Feb; 24(1):e13766. PubMed ID: 34799964
[TBL] [Abstract][Full Text] [Related]
4. Real-world experience of Quantiferon-CMV directed prophylaxis in lung transplant recipients.
Gardiner BJ; Lee SJ; Robertson AN; Cristiano Y; Snell GI; Morrissey CO; Peleg AY; Westall GP
J Heart Lung Transplant; 2022 Sep; 41(9):1258-1267. PubMed ID: 35868965
[TBL] [Abstract][Full Text] [Related]
5. An Interventional Study Using Cell-Mediated Immunity to Personalize Therapy for Cytomegalovirus Infection After Transplantation.
Kumar D; Mian M; Singer L; Humar A
Am J Transplant; 2017 Sep; 17(9):2468-2473. PubMed ID: 28500691
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.
Chiereghin A; Potena L; Borgese L; Gibertoni D; Squarzoni D; Turello G; Petrisli E; Piccirilli G; Gabrielli L; Grigioni F; Lazzarotto T
J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29305542
[TBL] [Abstract][Full Text] [Related]
7. Role of Secondary Prophylaxis With Valganciclovir in the Prevention of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients.
Gardiner BJ; Chow JK; Price LL; Nierenberg NE; Kent DM; Snydman DR
Clin Infect Dis; 2017 Nov; 65(12):2000-2007. PubMed ID: 29020220
[TBL] [Abstract][Full Text] [Related]
8. Cellular Immunity to Predict the Risk of Cytomegalovirus Infection in Kidney Transplantation: A Prospective, Interventional, Multicenter Clinical Trial.
Jarque M; Crespo E; Melilli E; Gutiérrez A; Moreso F; Guirado L; Revuelta I; Montero N; Torras J; Riera L; Meneghini M; Taco O; Manonelles A; Paul J; Seron D; Facundo C; Cruzado JM; Gil Vernet S; Grinyó JM; Bestard O
Clin Infect Dis; 2020 Dec; 71(9):2375-2385. PubMed ID: 32076718
[TBL] [Abstract][Full Text] [Related]
9. Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.
San-Juan R; Navarro D; García-Reyne A; Montejo M; Muñoz P; Carratala J; Len O; Fortun J; Muñoz-Cobo B; Gimenez E; Eworo A; Sabe N; Meije Y; Martín-Davila P; Andres A; Delgado J; Jimenez C; Amat P; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Aguado JM;
Transpl Infect Dis; 2015 Oct; 17(5):637-46. PubMed ID: 26134282
[TBL] [Abstract][Full Text] [Related]
10. Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients.
La Rosa C; Limaye AP; Krishnan A; Blumstein G; Longmate J; Diamond DJ
Transpl Int; 2011 Sep; 24(9):920-31. PubMed ID: 21672050
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon-γ release assay in kidney transplant recipients treated with antithymocyte globulin.
Fernández-Ruiz M; Rodríguez-Goncer I; Parra P; Ruiz-Merlo T; Corbella L; López-Medrano F; Polanco N; González E; San Juan R; Folgueira MD; Andrés A; Aguado JM
Am J Transplant; 2020 Aug; 20(8):2070-2080. PubMed ID: 31991045
[TBL] [Abstract][Full Text] [Related]
12. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients.
Eid AJ; Arthurs SK; Deziel PJ; Wilhelm MP; Razonable RR
Am J Transplant; 2010 Jan; 10(1):157-61. PubMed ID: 19889123
[TBL] [Abstract][Full Text] [Related]
13. Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study.
Korneffel K; Mitro G; Buschor K; Rees M; Ortiz J
Transpl Immunol; 2019 Oct; 56():101226. PubMed ID: 31344441
[TBL] [Abstract][Full Text] [Related]
14. Role of cytomegalovirus specific cell-mediated immunity in the monitoring of cytomegalovirus infection among living donor liver transplantation adult recipients: A single-center experience.
Bhugra A; Khodare A; Agarwal R; Pamecha V; Gupta E
Transpl Infect Dis; 2023 Feb; 25(1):e14011. PubMed ID: 36602403
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients With a High Risk of CMV Disease (D+/R-): A Case Series.
Andreani M; Albano L; Benzaken S; Cassuto E; Jeribi A; Caramella A; Giordanengo V; Bernard G; Esnault V; Seitz-Polski B
Transplant Proc; 2020; 52(1):204-211. PubMed ID: 31889538
[TBL] [Abstract][Full Text] [Related]
16. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients.
Kumar D; Chernenko S; Moussa G; Cobos I; Manuel O; Preiksaitis J; Venkataraman S; Humar A
Am J Transplant; 2009 May; 9(5):1214-22. PubMed ID: 19422346
[TBL] [Abstract][Full Text] [Related]
17. Immunoguided Discontinuation of Prophylaxis for Cytomegalovirus Disease in Kidney Transplant Recipients Treated With Antithymocyte Globulin: A Randomized Clinical Trial.
Páez-Vega A; Gutiérrez-Gutiérrez B; Agüera ML; Facundo C; Redondo-Pachón D; Suñer M; López-Oliva MO; Yuste JR; Montejo M; Galeano-Álvarez C; Ruiz-San Millan JC; Los-Arcos I; Hernández D; Fernández-Ruiz M; Muñoz P; Valle-Arroyo J; Cano A; Rodríguez-Benot A; Crespo M; Rodelo-Haad C; Lobo-Acosta MA; Garrido-Gracia JC; Vidal E; Guirado L; Cantisán S; Torre-Cisneros J;
Clin Infect Dis; 2022 Mar; 74(5):757-765. PubMed ID: 34228099
[TBL] [Abstract][Full Text] [Related]
18. Reliability of QuantiFERON®-CMV in predicting CMV recurrence in heart transplant recipients: A single-center retrospective study.
Sermet K; Goeminne C; Hantz S; Assaf A; Faure E; Lazrek M; Faure K; Alain S; Vuotto F
Clin Transplant; 2023 Dec; 37(12):e15109. PubMed ID: 37641575
[TBL] [Abstract][Full Text] [Related]
19. A Randomized Study of Quantiferon CMV-directed Versus Fixed-duration Valganciclovir Prophylaxis to Reduce Late CMV After Lung Transplantation.
Westall GP; Cristiano Y; Levvey BJ; Whitford H; Paraskeva MA; Paul E; Peleg AY; Snell GI
Transplantation; 2019 May; 103(5):1005-1013. PubMed ID: 30247316
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors of spontaneous CMV DNAemia clearance in kidney transplantation.
Noble J; Gatault P; Sautenet B; Gaudy-Graffin C; Beby-Defaux A; Thierry A; Essig M; Halimi JM; Munteanu E; Alain S; Buchler M
J Clin Virol; 2018; 99-100():38-43. PubMed ID: 29306112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
